Compare YMT & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YMT | VYNE |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 20.4M |
| IPO Year | N/A | 2017 |
| Metric | YMT | VYNE |
|---|---|---|
| Price | $0.22 | $0.63 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 13.4M | 118.1K |
| Earning Date | 06-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.29 |
| 52 Week High | $2.40 | $1.98 |
| Indicator | YMT | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 32.00 | 59.63 |
| Support Level | $0.15 | $0.56 |
| Resistance Level | $0.35 | $0.75 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 31.78 | 99.82 |
Yimutian Inc is the largest agricultural B2B platform in mainland China. It provide a comprehensive set of digital solutions to facilitate agricultural product transactions, ranging from searching, matching, to transaction facilitation and settlement. The company pride itself as the go-to platform for merchants by leveraging its inventive technology and industry know-how. Its platform had over 38 million merchants. It has also established approximately 12 offline stores in mainland China to trade agricultural products at cultivation and production sites with sellers and buyers.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.